NRAS and cancer: While mutations at Q61 compose 60% of NRAS mutations in other cancers [14], we find this rate to be over 80% in MM likely due to the increased rate of NRAS mutations at Q61 observed in HRD and t(11;14) myeloma—subgroups that comprise the majority of MM.